Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Novartis, Shire On Misbranding

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire pulls Fosrenol promos, calling them an “an unfortunate error.”

You may also be interested in...



Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.

Related Content

Topics

UsernamePublicRestriction

Register

PS067880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel